adjuvant chemotherapy

ctDNA-Guided Adjuvant Therapy in Stage III Colon Cancer: DYNAMIC-III Validates Prognosis but Questions Intensification

By MedXY 11/13/2025

The randomized phase 2/3 DYNAMIC-III trial shows that postoperative circulating tumor DNA (ctDNA) strongly stratifies recurrence risk in stage III colon cancer. ctDNA-guided de-escalation reduced oxaliplatin exposure and hospitalizations with outcomes close to standard care; escalation for ctDNA-positive disease did not improve recurrence-free survival.

Gastroenterology news Oncology

Proteogenomic Insights into Personalized Adjuvant Chemotherapy for Extrahepatic Cholangiocarcinoma

By MedXY 10/28/2025

Comprehensive proteogenomic profiling in resected extrahepatic cholangiocarcinoma reveals predictive biomarkers for tailoring adjuvant chemotherapy, offering a precision medicine approach to improve patient outcomes.

General Surgery news Oncology

Defining Cure in Stage II-III Colon Cancer: Insights from a Pooled Analysis of 15 Randomized Trials

By MedXY 10/04/2025

A rigorous pooled analysis of over 35,000 patients identifies a recurrence risk below 0.5% at 6 years post-surgery, providing a practical benchmark for defining cure in stage II-III colon cancer and refining patient management strategies.

Clinical Updates news Oncology Pathology & Lab Medicine Specialties

Predictive Power of Circulating Tumor DNA in Managing Resected Extrahepatic Cholangiocarcinoma

By MedXY 09/20/2025

Monitoring circulating tumor DNA (ctDNA) post-surgery accurately predicts recurrence risk in extrahepatic cholangiocarcinoma, guiding personalized adjuvant chemotherapy decisions and improving patient outcomes.

Clinical Updates news Oncology Radiology Specialties

Induction vs Adjuvant Chemoradiotherapy in High-Risk N2-N3 Nasopharyngeal Carcinoma: Insights from a Phase 3 Randomized Trial

By MedXY 09/12/2025

This phase 3 trial compares induction-concurrent chemotherapy with concurrent-adjuvant chemotherapy in high-risk N2 to N3 nasopharyngeal carcinoma, finding no significant difference in 3-year progression-free survival while highlighting distinct safety profiles.

Oncology Radiology Specialties

Comparative Efficacy of Induction-Concurrent Versus Concurrent-Adjuvant Chemoradiotherapy in High-Risk N2-N3 Nasopharyngeal Carcinoma: Insights from a Phase 3 Randomized Trial

By MedXY 08/23/2025

A phase 3 trial showed no significant difference in 3-year progression-free survival between induction-concurrent and concurrent-adjuvant chemoradiotherapy in treating high-risk N2-N3 nasopharyngeal carcinoma, with both regimens exhibiting manageable safety profiles.

Family Medicine & Nutrition news Oncology Specialties

Structured Exercise after Adjuvant Chemotherapy for Colon Cancer: Impact on Survival Outcomes

By MedXY 08/19/2025

A 3-year structured exercise program post-adjuvant chemotherapy significantly improves disease-free and overall survival in colon cancer patients, based on the CHALLENGE phase 3 RCT involving 889 patients.

Clinical Updates Oncology Specialties

No Added Survival Benefit from Adjuvant Chemotherapy in Older Women with Genomically High-Risk Hormone Receptor-Positive Breast Cancer: Results from the ASTER 70s Trial

By MedXY 08/07/2025

The ASTER 70s trial found that adding chemotherapy to hormonotherapy did not improve survival but increased toxicity in women aged 70+ with high-risk ER+/HER2- breast cancer.